CRClaudio Rigatto

Claudio Rigatto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Claudio Rigatto has a total of 336 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Randomized Controlled Trial of Intradialytic Cycling as Kidney Exercise Rehabilitation for Cardiac Stunning in Hemodialysis (TICKERS_HD): A Clinical Research Protocol

    by Paul N. Bennett, Jarrin D. Penny, Christopher W. McIntyre, Jessica Vanderlinden, Megan S. Borkum, Gisell Castillo, David Collister, Bonnie Corradetti, Todd A. Duhamel, Haley Farion, et al.

    Introduction: People with hemodialysis-dependent kidney failure experience significantly higher cardiovascular (CV) morbidity, mortality, symptom burden, and cognitive impairment compared to the general population. Hemodialysis-induced ischemia contributes to myocardial stunning, which worsens CV outcomes. Intradialytic cycling has the potential to mitigate cardiac stunning, but its effects have not been assessed in randomized controlled trials (RCTs). Methods: This multicenter RCT evaluates the impact of 12 weeks of intradialytic cycling on hemodialysis-induced myocardial stunning. The study will recruit 160 adults (80 intervention and 80 control) receiving maintenance hemodialysis at five Canadian centers and one Australian center. Outcome assessments are conducted at baseline, 12 weeks, and 16 weeks. An intervention implementation process evaluation is part of this study. Outcomes: The primary outcome is change in number of regional wall motion abnormalities (RWMAs) at peak hemodialysis stress from baseline to 12 weeks. Secondary outcomes include changes in cognitive function, hemodialysis recovery time, and symptom burden. Statistical Analysis: Change in number of RWMAs at peak hemodialysis stress from baseline to 12 weeks are compared between study groups using an independent 2-tailed t test and using a Poisson generalized linear mixed model with study group as a fixed effect, and time and mean ultrafiltration rate as random effects. Conclusion: Compared with standard care, we anticipate that intradialytic cycling will decrease myocardial stunning, resulting in improved symptom burden, and functional and cognitive status. This trial provides critical evidence regarding the benefits and feasibility of exercise during hemodialysis, potentially informing clinical practice, and guidelines for hemodialysis care. Trial registration number: NCT04877041


  • Open Access

    A Pragmatic Randomized Controlled Trial of a CKD-Specific Virtual Monitoring Platform to Minimize Adverse Outcomes in High-Risk CKD Patients: A Clinical Research Protocol

    by Zahra Solati, Paul Komenda, Navdeep Tangri, Sakshi Saul, Clara Bohm, Thomas Ferguson, Drew Hager, Bryce Barr, Priyanka Mysore, Ingrid Hougen, et al.

    Background: The transition from advanced Chronic Kidney Disease (CKD) to dialysis is a period of heightened vulnerability for many patients. Virtual monitoring of these patients could facilitate the communication of accurate and reliable data between patients and health care providers, helping to avoid unnecessary emergency department (ED) visits and facilitate more optimal dialysis starts. Objective: To determine whether the addition of the VIEWER (Virtual Ward Incorporating Electronic Wearables) platform to usual care will lead to a reduction in ED visits and hospitalizations and lead to an increase in perceived safety of virtual care among patients and providers. Design: This study is a national, pragmatic, multicenter randomized controlled trial comparing usual care alone vs usual care plus the VIEWER virtual care platform in patients with advanced CKD. Given the nature of the intervention, patients and care providers will not be blinded; outcome assessment and statistical analysis will be blinded. Setting: Five CKD clinics in 2 Canadian provinces (Manitoba and Ontario). Participants: Patients with advanced CKD not on dialysis (eGFR 40%). Measurements: Participants randomized to the intervention group will be provided with the VIEWER platform, comprised of a wireless blood pressure (BP) monitor, weight scale, transcutaneous O 2 sat (SpO2) monitor, wearable motion tracker, and mobile tablet running the VIEWER application. The intervention group will be trained to use the VIEWER platform to complete a daily self-assessment via the app (BP, weight, O 2 saturation, step count) and weekly Edmonton Symptom Assessment System Revised (ESAS-r) survey. These assessments will be integrated into clinical decision-making in multidisciplinary kidney health clinics. Participants will use the VIEWER platform for 12 months (or until dialysis initiation) in addition to receiving usual care. Methods: Intention-to-treat (ITT) approach will be used to compare the primary outcome between 2 study groups. Time to primary and secondary outcomes will be assessed using univariate Cox proportional hazards models and a Kaplan-Meier analysis with a log-rank test. The primary outcome is the time to first hospital admission and/or ED visit. The control is usual care (no exposure to VIEWER platform). Limitations: Some individuals may face challenges with technology adoption, which could affect participation. Those without Internet access are limited in their ability to take part in this study. Conclusions: This study will help determine whether virtual monitoring in advanced CKD patients can reduce ED visits and hospitalization. Trial registration: Clinicaltrials.gov; identifier: NCT05726526.


  • (undefined)

    by Zahra Solati, Paul Komenda, Navdeep Tangri, Sakshi Saul, Clara Bohm, Thomas Ferguson, Drew Hager, Bryce Barr, Priyanka Mysore, Ingrid Hougen, et al.

    Background: The transition from advanced Chronic Kidney Disease (CKD) to dialysis is a period of heightened vulnerability for many patients. Virtual monitoring of these patients could facilitate the communication of accurate and reliable data between patients and health care providers, helping to avoid unnecessary emergency department (ED) visits and facilitate more optimal dialysis starts. Objective: To determine whether the addition of the VIEWER (Virtual Ward Incorporating Electronic Wearables) platform to usual care will lead to a reduction in ED visits and hospitalizations and lead to an increase in perceived safety of virtual care among patients and providers. Design: This study is a national, pragmatic, multicenter randomized controlled trial comparing usual care alone vs usual care plus the VIEWER virtual care platform in patients with advanced CKD. Given the nature of the intervention, patients and care providers will not be blinded; outcome assessment and statistical analysis will be blinded. Setting: Five CKD clinics in 2 Canadian provinces (Manitoba and Ontario). Participants: Patients with advanced CKD not on dialysis (eGFR 40%). Measurements: Participants randomized to the intervention group will be provided with the VIEWER platform, comprised of a wireless blood pressure (BP) monitor, weight scale, transcutaneous O 2 sat (SpO2) monitor, wearable motion tracker, and mobile tablet running the VIEWER application. The intervention group will be trained to use the VIEWER platform to complete a daily self-assessment via the app (BP, weight, O 2 saturation, step count) and weekly Edmonton Symptom Assessment System Revised (ESAS-r) survey. These assessments will be integrated into clinical decision-making in multidisciplinary kidney health clinics. Participants will use the VIEWER platform for 12 months (or until dialysis initiation) in addition to receiving usual care. Methods: Intention-to-treat (ITT) approach will be used to compare the primary outcome between 2 study groups. Time to primary and secondary outcomes will be assessed using univariate Cox proportional hazards models and a Kaplan-Meier analysis with a log-rank test. The primary outcome is the time to first hospital admission and/or ED visit. The control is usual care (no exposure to VIEWER platform). Limitations: Some individuals may face challenges with technology adoption, which could affect participation. Those without Internet access are limited in their ability to take part in this study. Conclusions: This study will help determine whether virtual monitoring in advanced CKD patients can reduce ED visits and hospitalization. Trial registration: Clinicaltrials.gov; identifier: NCT05726526.

  • Comparing Frailty Assessment Methods and Their Ability to Predict Adverse Outcomes in Patients with Advanced CKD

    by Hailey V. Hildebrand, Oksana Harasemiw, Ranveer Brar, Paul Komenda, Claudio Rigatto, Bhanu Prasad, Clara Bohm, Navdeep Tangri

    Key Points: Most measures of frailty, regardless of definition used, were associated with higher risk of mortality, hospitalizations, and emergency room visits. Claims-based definitions had poor agreement when compared with objective and subjective measures of frailty in the advanced CKD population. Administrative definitions require further development to accurately identify frail patients in the advanced CKD population. Background: Frailty is common in patients with CKD, and those affected by both are at increased risk of adverse outcomes including disability, hospitalization, and death. Collecting data on frailty as part of clinical care could enhance care by identifying patients at risk of adverse events. However, clinical assessment of frailty requires time and resources. Frailty definitions based on administrative data might provide an efficient alternative. The primary objective was to compare agreement between administrative claims-based definitions versus objectively measured frailty in adults with advanced, nondialysis CKD and to examine their associations with adverse outcomes. Methods: The cohort consisted of Manitoba participants from the Canadian Frailty Observation and Interventions Trial. This multicenter cohort study followed adults with advanced CKD longitudinally. Every visit, assessments were conducted to determine frailty status using the Fried Frailty Phenotype, Short Physical Performance Battery, and health care providers' impression. The Canadian Frailty Observation and Interventions Trial database was linked to administrative databases at the Manitoba Centre for Health Policy to calculate two claims-based frailty indicators, the Segal and modified preoperative frailty indices, which have been validated in the non-CKD literature. Results: Of the 442 participants included, the mean age was 66±14 years and 58% were male; 88% had hypertension, 61% dyslipidemia, and 58% diabetes. The prevalence of frailty varied from 19% to 70% depending on definition. Agreement between frailty definitions was poor ( κ 0.09–0.33); however, individuals considered frail using both administrative or measured definitions had a higher risk of all-cause mortality and hospitalization, except for those identified by the Segal Frailty Indicator. Conclusions: This study suggests that those identified as frail by nearly all measures were at higher risk of adverse outcomes. Thus, most frailty models in this study can be used to identify high risk advanced nondialysis CKD populations, allowing us to target individuals for interventions that aim to improve outcomes.


  • Open Access

    A passive flow microreactor for urine creatinine test

    by Dumitru Tomsa, Yang Liu, Amanda Stefanson, Xiaoou Ren, AbdulRazaq A. H. Sokoro, Paul Komenda, Navdeep Tangri, Rene P. Zahedi, Claudio Rigatto, Francis Lin

    Chronic kidney disease (CKD) significantly affects people’s health and quality of life and presents a high economic burden worldwide. There are well-established biomarkers for CKD diagnosis. However, the existing routine standard tests are lab-based and governed by strict regulations. Creatinine is commonly measured as a filtration biomarker in blood to determine estimated Glomerular Filtration Rate (eGFR), as well as a normalization factor to calculate urinary Albumin-to-Creatinine Ratio (uACR) for CKD evaluation. In this study, we developed a passive flow microreactor for colorimetric urine creatinine measurement (uCR-Chip), which is highly amenable to integration with our previously developed microfluidic urine albumin assay. The combination of the 2-phase pressure compensation (2-PPC) technique and microfluidic channel network design accurately controls the fluidic mixing ratio and chemical reaction. Together with an optimized observation window (OW) design, a uniform and stable detection signal was achieved within 7 min. The color signal was measured by a simple USB microscope-based platform to quantify creatinine concentration in the sample. The combination of the custom in-house photomask production techniques and dry-film photoresist-based lithography enabled rapid iterative design optimization and precise chip fabrication. The developed assay achieved a dynamic linear detection range up to 40 mM and a lower limit of detection (LOD) of 0.521 mM, meeting the clinical precision requirements (comparable to existing point-of-care (PoC) systems). The microreactor was validated using creatinine standards spiked into commercial artificial urine that mimics physiological matrix. Our results showed acceptable recovery rate and low matrix effect, especially for the low creatinine concentration range in comparison to a commercial PoC uACR test. Altogether, the developed uCR-Chip offers a viable PoC test for CKD assessment and provides a potential platform technology to measure various disease biomarkers.


  • Open Access

    Cultivating Innovative, Pragmatic, Randomized Controlled Registry Trials Embedded in Hemodialysis Care: Conference Proceeding From Gardener’s Grove 2023

    by Bryn Tannar, Patricia Olar, Shane Kilburn, Kathleen Brown-Blake, Ahmed A. Al-Jaishi, Peter G. Blake, Kristin K. Clemens, Charles Cook, Laura M. Dember, Stephanie N. Dixon, et al.

    Purpose of the Conference: Hemodialysis is a life-sustaining treatment for patients with end-stage kidney disease. However, patients on dialysis continue to face poor quality of life and short life expectancies. Despite this, the nephrology community conducts the fewest randomized controlled trials of any medical discipline, relying instead on expert opinion to guide many aspects of hemodialysis care. There is a need to conduct high-quality pragmatic randomized controlled trials in hemodialysis to drive evidence-based practice. To this end, the Innovative Clinical Trials in Hemodialysis Centers initiative, with the support of the Canadian Institutes of Health Research and its Strategy for Patient-Oriented Research, funded the development of 6 pragmatic trial protocols. Gardener’s Grove 2023 created a space to support the development of these trials and increase awareness and knowledge of past, ongoing, and future innovative, pragmatic, randomized controlled registry trials embedded in routine hemodialysis care. This report summarizes the proceedings of this conference. Sources of information: The conference included 6 panel presentations, each featuring an overview of a new pragmatic trial followed by expert panel feedback from patient partners, nephrologists, researchers, and health care providers. The conference also included 10 educational sessions led by clinicians and researchers with experience in the fields of kidney medicine and clinical trials. Methods: Gardener’s Grove 2023 was a 4-day virtual conference held in March of 2023. Recordings of all the conference presentations were later published on the Gardener’s Grove website and are summarized in the Supplemental Appendix of this report. Key Findings: The conference brought together 118 Canadian and international researchers, patients, and health care providers to collaborate on 6 pragmatic trials intended to test interventions to improve hemodialysis care. The proposed trials included (1) PREventing FracturEs in REnal Disease (PREFERRED), (2) DIALysis with EXpanded solute removal (DIALEX), (3) Sodium fOr diaLysis oUTcome rEduction (SOLUTE), (4) Finding the right blood pressure target for patients on dialysis, (5) DIuretic Use in patients with Residual renal function on hemodialysis (DIURESED), and (6) Lower vs higher dialysate bicarbonate concentration in patients receiving hemodialysis (Dial-Bicarb). All of these interventions were widely supported and received valuable feedback from panelists and conference attendees. The education sessions focused on various design and execution elements of pragmatic, randomized controlled registry trials embedded in routine care. Limitations: The conference could have been improved by streamlining session topics and pacing, allowing additional time for discussions, strengthening online network opportunities, and improving survey response rates. A follow-up conference is planned to take place in a few years, and the coordinators will aim to implement these changes. Implications: Gardener’s Grove 2023 successfully created a space for patients, researchers, and health care providers to support the development of 6 new pragmatic trials in hemodialysis care. Since Gardener’s Grove 2023, several of these trials have secured CIHR funding, obtained ethics approval, and are actively preparing to launch their interventions.

  • Evaluation of an online cardiometabolic and weight loss program: a mixed methods study

    by Dianna A. Dandeneau, Silvia J. Leon, Margherita Cameranesi, Mackenzie R. Alexiuk, Jennifer L. P. Protudjer, Clara J. Bohm, Michelle S. J. DiNella, Carrie K. Solmundson, Melanie Talson, Haizhou Wang, et al.

    Risk factors contributing to cardiovascular diseases (CVD) can be addressed through behavior modification, including changes in diet and physical activity. In 2021, The Wellness Institute (WI), located at Seven Oaks General Hospital, created a virtual cardiometabolic risk reduction program in response to COVID-19 pandemic public health restrictions, encompassing virtual health coaching and lifestyle education. The objective was to evaluate the acceptability, adherence, efficacy, and engagement of the WI online cardiometabolic and weight loss program. The study followed a mixed methods quasi-experimental design. A total of 93 participants enrolled. Quantitative measures including anthropometrics, blood chemistry, and lifestyle were assessed for changes via paired t tests at baseline and 16 weeks. Qualitatively, short answer questionnaires and three focus groups were completed to understand participants’ experiences and program acceptability. We combined qualitative and quantitative data for analysis. Seventy-three participants (64 females, 87.7%) completed the final study visit (age 58 ± 11 years, weight 98 ± 20.9 kg). Of those, 98% attended all coaching sessions, would recommend the program, and reported the coaching sessions helped them stay motivated. A reduction in weight (5 ± 9 kg, p < 0.001), systolic blood pressure (6 ± 10 mmHg, p < 0.001), and diastolic blood pressure (4 ± 8 mmHg, p < 0.001) were observed. Lifestyle factors also improved, including increases in physical activity ( p < 0.05). Most participants adhered to the program and found it acceptable. Completion was associated with an improvement in weight and blood pressure. These findings highlight the potential of virtual programming to contribute to improving lifestyle and health. Clinicaltrials.gov (ID# NCT04784624CT).


  • Anticoagulation for Patients with Atrial Fibrillation Receiving Dialysis

    by Ziv Harel, Brendan Smyth, Sunil V. Badve, Daniel Blum, William Beaubien-Souligny, Samuel A. Silver, Edward Clark, Rita Suri, Thomas A. Mavrakanas, Joanna Sasal, et al.

    Key Points: Is performing a large definitive trial to establish the optimal anticoagulation strategy in dialysis recipients with atrial fibrillation feasible? One hundred fifty-one patients at 28 dialysis centers were enrolled and randomized to apixaban ( n =51), warfarin ( n =52), or no oral anticoagulation ( n =48). Despite coronavirus disease–related pauses, recruitment was completed in 30 months, with 83% of participants completing follow-up in their assigned treatment arm. Background: Atrial fibrillation is common in individuals receiving dialysis. The role of oral anticoagulation in this population is uncertain given its exclusion from previous seminal clinical trials. Our objective was to determine the feasibility of performing a large definitive trial to establish the optimal anticoagulation strategy in individuals with atrial fibrillation receiving dialysis. Methods: The Strategies for the Management of Atrial Fibrillation in Patients Receiving Dialysis trial was a parallel-group, open-label, allocation-concealed, pilot randomized control trial that took place at 28 centers in Canada and Australia. The trial included adults (18 years or older) undergoing dialysis with a history of nonvalvular atrial fibrillation who met the CHADS-65 criteria. Participants were randomized 1:1:1 to receive dose-adjusted warfarin, apixaban 5 mg twice daily, or no oral anticoagulation and followed for 26 weeks. The primary outcomes evaluated the following measures of feasibility: ( 1 ) recruitment of the target population within 2 years from the start of the trial and ( 2 ) adherence of >80% of randomized patients to the allocated treatment strategy at the conclusion of follow-up. Secondary outcomes included stroke and bleeding. Results: From December 2019 to June 2022, 151 patients were enrolled and randomized to apixaban ( n =51), warfarin ( n =52), or no oral anticoagulation ( n =48). Allowing for pauses related to the coronavirus disease pandemic, recruitment was completed in 30 months, and 123 (83%) of participants completed follow-up in their allocated treatment arm. There was one adjudicated stroke event. Eight participants had a major bleeding event (four warfarin, two apixaban, two no oral anticoagulation). Death occurred in 15 participants (nine warfarin, two apixaban, four no oral anticoagulation). Time in the therapeutic range for warfarin recipients was 58% (interquartile range, 47%–70%). Conclusions: We have demonstrated the feasibility of recruitment and adherence in a trial that compared different anticoagulation strategies in patients with atrial fibrillation receiving dialysis. Clinical Trial registry name and registration number: Strategies for the Management of Atrial Fibrillation in Patients Receiving Dialysis (SAFE-D), NCT03987711. Podcast: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/JASN/2025_04_09_ASN0000000000000495.mp3


  • Prevalence and Outcomes of Chronic Kidney Disease-Associated Pruritus

    by Karthik K. Tennankore, Keith McCullough, Brian Bieber, Yeoungjee Cho, David W. Johnson, Talerngsak Kanjanabuch, Hideki Kawanishi, Yong-Lim Kim, Mark Lambie, Claudio Rigatto, et al.

    Key Points: CKD-associated pruritus is highly prevalent among peritoneal dialysis patients. Pruritus is associated with reduced health-related quality of life, and the composite of mortality and transfer to hemodialysis for peritoneal dialysis patients. Efforts to better identify and manage pruritus in this population are needed. Background: Pruritus is common in hemodialysis patients. Less is known about the prevalence and outcomes of pruritus among patients receiving peritoneal dialysis (PD). Herein, we describe the prevalence of pruritus and its associations with patient-reported outcomes (PROs) and mortality/transfer to hemodialysis. Methods: We analyzed a multicenter, international cohort of PD patients enrolled in the PD Outcomes and Practice Patterns Study from 2014 to 2022. Pruritus was assessed at entry into the PD Outcomes and Practice Patterns Study with a single-question Likert Scale capturing the extent to which patients were bothered by itch ranging from 1: not at all to 5: extremely . The kidney disease quality of life-36 and the Center for Epidemiological Studies Depression Scale assessed various PROs. Moderate-to-extreme pruritus was defined as a Likert scale score ≥3. The associations of pruritus with PROs were assessed using linear/logistic regression where appropriate. Death or hemodialysis transfer was assessed using multivariable Cox regression models. Results: Overall, 5535 patients from eight countries were included; 43% had moderate-to-extreme pruritus which was the highest in Thailand (50%) and the lowest in the United States (33%). The adjusted odds ratios of moderate-to-extreme pruritus were higher for diabetes, low albumin, and elevated phosphorus but lower for residual urine volume (adjusted odds ratio, 0.98 per 200 ml increase in 24-hour urine volume; 95% confidence interval, 0.96 to 1.00; P = 0.05). Patients with extreme pruritus had the lowest mental and physical health component scores and a higher burden of other PROs including restless legs and disturbed sleep. Overall, 921 patients died and 1150 were transferred to hemodialysis. Patients with moderate-to-extreme pruritus were at higher adjusted risk for death or hemodialysis transfer (adjusted hazard ratio, 1.12; 95% confidence interval, 1.02 to 1.23; P = 0.02) with similar point estimates for each subcomponent of the composite outcome. Conclusions: Pruritus is highly prevalent in PD and associated with poor health outcomes. Efforts to better identify and manage pruritus should be considered in this population.


  • Open Access

    Expanding Access to High KDPI Kidney Transplant for Recipients Aged 60 y and Older: Cost Utility and Survival

    by Ryan J. Msc Bamforth, Aaron Trachtenberg, Julie Ho, Chris Wiebe, Thomas W. Msc Ferguson, Claudio Rigatto, Evelyn Forget, Nancy Peng Dodd, Navdeep Tangri

    Background. Modern organ allocation systems are tasked with equitably maximizing the utility of transplanted organs. Increasing the use of deceased donor organs at risk of discard may be a cost-effective strategy to improve overall transplant benefit. We determined the survival implications and cost utility of increasing the use of marginal kidneys in an older adult Canadian population of patients with end-stage kidney disease. Methods. We constructed a cost-utility model with microsimulation from the perspective of the Canadian single-payer health system for incident transplant waitlisted patients aged 60 y and older. A kidney donor profile index score of ≥86 was considered a marginal kidney. Donor- and recipient-level characteristics encompassed in the kidney donor profile index and estimated posttransplant survival scores were used to derive survival posttransplant. Patients were followed up for 10 y from the date of waitlist initiation. Our analysis compared the routine use of marginal kidneys (marginal kidney scenario) with the current practice of limited use (status quo scenario). Results. The 10-y mean cost and quality-adjusted life-years per patient in the marginal kidney scenario were estimated at $379 485.33 (SD: $156 872.49) and 4.77 (SD: 1.87). In the status quo scenario, the mean cost and quality-adjusted life-years per patient were $402 937.68 (SD: $168 508.85) and 4.37 (SD: 1.87); thus, the intervention was considered dominant. At 10 y, 62.8% and 57.0% of the respective cohorts in the marginal kidney and status quo scenarios remained alive. Conclusions. Increasing the use of marginal kidneys in patients with end-stage kidney disease aged 60 y and older may offer cost savings, improved quality of life, and greater patient survival in comparison with usual care. Export